Brokerages Set Novo Nordisk A/S (NYSE:NVO) PT at $81.00

Key Points

• Analysts have given Novo Nordisk A/S an average recommendation of "Hold", with one sell, eleven hold, and three buy ratings among fifteen analysts.
• The company's stock price target among analysts is $81.00, with its recent trading price around $54.30.
• Novo Nordisk recently reported earnings of $0.97 per share, exceeding expectations, while also announcing a semi-annual dividend of $0.4119 per share.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) has been assigned an average recommendation of "Hold" from the sixteen ratings firms that are covering the firm, MarketBeat reports. Two investment analysts have rated the stock with a sell recommendation, eleven have assigned a hold recommendation and three have assigned a buy recommendation to the company. The average 1-year target price among brokerages that have issued ratings on the stock in the last year is $81.00.

Several research firms have recently commented on NVO. BNP Paribas Exane upgraded Novo Nordisk A/S from an "underperform" rating to a "neutral" rating and set a $54.00 price target on the stock in a report on Wednesday, August 13th. Barclays reissued an "equal weight" rating on shares of Novo Nordisk A/S in a research report on Wednesday, July 30th. BNP Paribas raised Novo Nordisk A/S from an "underperform" rating to a "neutral" rating in a research report on Wednesday, August 13th. TD Cowen cut their price objective on Novo Nordisk A/S from $105.00 to $70.00 and set a "buy" rating for the company in a research report on Tuesday, August 19th. Finally, Hsbc Global Res downgraded Novo Nordisk A/S from a "strong-buy" rating to a "hold" rating in a research report on Thursday, July 31st.

Hedge Funds Weigh In On Novo Nordisk A/S

Several institutional investors have recently bought and sold shares of NVO. Copeland Capital Management LLC grew its position in Novo Nordisk A/S by 184.8% in the 1st quarter. Copeland Capital Management LLC now owns 393 shares of the company's stock valued at $27,000 after acquiring an additional 255 shares in the last quarter. North Capital Inc. acquired a new position in shares of Novo Nordisk A/S during the first quarter worth about $27,000. Park Square Financial Group LLC acquired a new position in shares of Novo Nordisk A/S during the fourth quarter worth about $29,000. Stone House Investment Management LLC acquired a new position in shares of Novo Nordisk A/S during the first quarter worth about $30,000. Finally, NewSquare Capital LLC grew its position in shares of Novo Nordisk A/S by 174.1% during the second quarter. NewSquare Capital LLC now owns 444 shares of the company's stock worth $31,000 after buying an additional 282 shares in the last quarter. 11.54% of the stock is owned by institutional investors and hedge funds.

Novo Nordisk A/S Price Performance

Novo Nordisk A/S stock traded up $1.4410 during trading on Thursday, reaching $56.8910. The company had a trading volume of 17,869,499 shares, compared to its average volume of 29,123,660. The firm's 50-day simple moving average is $62.57 and its 200 day simple moving average is $69.33. The company has a debt-to-equity ratio of 0.52, a quick ratio of 0.56 and a current ratio of 0.78. The firm has a market capitalization of $254.02 billion, a PE ratio of 15.63, a price-to-earnings-growth ratio of 1.98 and a beta of 0.63. Novo Nordisk A/S has a 1-year low of $45.05 and a 1-year high of $139.74.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last announced its quarterly earnings data on Wednesday, August 6th. The company reported $0.97 earnings per share for the quarter, beating analysts' consensus estimates of $0.93 by $0.04. The company had revenue of $11.69 billion for the quarter, compared to analyst estimates of $77.51 billion. Novo Nordisk A/S had a return on equity of 78.64% and a net margin of 35.60%. As a group, equities research analysts anticipate that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Novo Nordisk A/S Cuts Dividend

The company also recently announced a semi-annual dividend, which will be paid on Tuesday, August 26th. Shareholders of record on Monday, August 18th will be given a $0.4119 dividend. This represents a yield of 240.0%. The ex-dividend date of this dividend is Monday, August 18th. Novo Nordisk A/S's payout ratio is currently 22.53%.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.